I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared carebroad
I-SCREEN · Horizon Europe grant · 2024-01-01–2028-12-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-PATHFINDEROPEN-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2023-PATHFINDEROPEN-01-01. CORDIS record →
Objective
The aim of I(eye)-Screen is to develop an artificial intelligence (AI)-based diagnostic decision support system for screening and monitoring of age-related macular degeneration (AMD) at an early stage before vision loss occurs. Late AMD is the leading cause of legal blindness >50 years with 110 mio individuals at risk. The multidisciplinary consortium brings together a network of clinical retina experts, computer scientists working at the cutting edge of AI development, an infrastructure of community-based opticians/optometrists and an SME experienced in digital platform performance to develop innovative and trustworthy AI tools for broad, real-time AMD screening and monitoring via a cloud-based infrastructure with unlimited access. To achieve the ambitious goal of finding “the needle in the haystack” in early AMD, Optical Coherence Tomography (OCT), a high-resolution, effortless imaging modality is used providing a detailed characterization of the retina in extensive volumetric scans. Breakthrough AI approaches for medical imaging will be developed to enable data-efficient and robust learning from sparse longitudinal OCT data to systematically analyse dense data volumes and identify (sub)clinical markers of disease activity. Clinical sites throughout Europe will collect a longitudinal cohort serving for calibrating and fine-tuning algorithms using the high-end OCT device available at eye clinics. Innovative AI technology will then be created to transfer the detection and monitoring tools to low-cost devices used in next door opticians’/optometrists’ offices. The timing of the project perfectly fits the recent regulatory approval of the first therapy to halt progression of the major atrophic type of AMD. The resulting AI-based “shared care” strategy offers unrestricted accessibility to vision-maintaining care with greatest health equity and provides a role model for screening for systemic, cardiovascular and neurodegenerative disease reflecting retinal biomarkers.
Beneficiaries (12)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| MEDIZINISCHE UNIVERSITAET WIEN | AT | coordinator | €1,333,540 | |
| RETINSIGHT GMBH | AT | participant | €1,116,900 | Yes |
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH | DE | participant | €345,000 | Yes |
| CENTRE HOSPITALIER REG UNIVERSITAIRE DIJON | FR | participant | €241,391 | |
| UNIVERZITETNI KLINICNI CENTER LJUBLJANA | SI | participant | €222,641 | |
| FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER | ES | participant | €195,141 | |
| RESEARCH AND INNOVATION SERVICES DOO ZA USLUGE | HR | thirdParty | €0 | Yes |
| HOSPITAL CLINIC DE BARCELONA | ES | thirdParty | €0 | |
| THE QUEEN'S UNIVERSITY OF BELFAST | UK | associatedPartner | — | |
| Vista Klinik Binningen | CH | associatedPartner | — | |
| European Council of Optometry and Optics | CH | associatedPartner | — | |
| UNIVERSITAT ZURICH | CH | associatedPartner | — |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.